Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor

(2013) Hagai Tavori et al.   CIRCULATION

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia

(2013) Paul Lee et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)

(2013) Rachel M. DeVay et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

(2013) Tanja Kosenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment

(2013) Kristian Tveten et al.   JOURNAL OF LIPID RESEARCH

Endosomal acidification by Na+/H+ exchanger NHE5 regulates TrkA cell-surface targeting and NGF-induced PI3K signaling

(2013) Graham H. Diering et al.   MOLECULAR BIOLOGY OF THE CELL

Releasable SNAP-tag Probes for Studying Endocytosis and Recycling

(2012) Nelson B. Cole et al.   ACS Chemical Biology

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

(2012) Yascara Grisel Luna Saavedra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The PCSK9 decade

(2012) Gilles Lambert et al.   JOURNAL OF LIPID RESEARCH

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

(2012) Yan Wang et al.   JOURNAL OF LIPID RESEARCH

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

(2012) Nabil G. Seidah et al.   PLoS One

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification

(2011) K. Tveten et al.   HUMAN MOLECULAR GENETICS

Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein

(2011) Fen Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ion flux and the function of endosomes and lysosomes: pH is just the start

(2010) Cameron C. Scott et al.   BIOESSAYS

A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor

(2010) Taichi Yamamoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The LDL Receptor

(2009) Joseph L. Goldstein et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

(2009) Marianne Abifadel et al.   HUMAN MUTATION

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Tickets to ride: selecting cargo for clathrin-regulated internalization

(2009) Linton M. Traub   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular basis of PCSK9 function

(2008) Gilles Lambert et al.   ATHEROSCLEROSIS

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels

(2008) Gaétan Mayer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice

(2008) Yi Luo et al.   JOURNAL OF LIPID RESEARCH

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

(2008) Aldo Grefhorst et al.   JOURNAL OF LIPID RESEARCH

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA